Clinical Trials in Minden, Germany
30 recruiting
Showing 1–20 of 38 trials
Recruiting
Phase 3
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
Ulcerative Colitis
AbbVie530 enrolled270 locationsNCT06880744
Recruiting
Phase 3
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
Acute Myeloid Leukemia
University of Ulm650 enrolled91 locationsNCT04628026
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Crohn's Disease
Merck Sharp & Dohme LLC1,200 enrolled497 locationsNCT06430801
Recruiting
Phase 2
Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients
First-line TreatmentBasal Cell Carcinoma (BCC)
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest34 enrolled7 locationsNCT06981325
Recruiting
Phase 2
A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
Crohn's Disease
Sanofi99 enrolled60 locationsNCT06958536
Recruiting
Phase 2
A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis
Ulcerative Colitis
Sanofi99 enrolled65 locationsNCT06975722
Recruiting
A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis
Relapsing Multiple Sclerosis
Novartis Pharmaceuticals800 enrolled111 locationsNCT05344469
Recruiting
A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis
Multiple Sclerosis
Novartis Pharmaceuticals700 enrolled108 locationsNCT06551519
Recruiting
A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)
Multiple Sclerosis
Hoffmann-La Roche842 enrolled74 locationsNCT06780150
Recruiting
Phase 3
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Small Cell Lung Cancer
Daiichi Sankyo540 enrolled230 locationsNCT06203210
Recruiting
Phase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
ObesityHeart Failure With Preserved Ejection FractionHeart Failure With Mildly Reduced Ejection Fraction
Amgen5,056 enrolled564 locationsNCT07037459
Recruiting
Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
AstraZeneca880 enrolled300 locationsNCT06692738
Recruiting
Phase 3
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Advanced Melanoma
Immunocore Ltd540 enrolled82 locationsNCT05549297
Recruiting
Phase 3
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
Advanced Melanoma
Immunocore Ltd680 enrolled211 locationsNCT06112314
Recruiting
Phase 3
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Non-small Cell Lung Cancer
Summit Therapeutics780 enrolled202 locationsNCT06767514
Recruiting
Phase 3
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Gilead Sciences695 enrolled204 locationsNCT06801834
Recruiting
Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative Colitis
Ulcerative Colitis
AbbVie200 enrolled55 locationsNCT06764706
Recruiting
Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
Non-squamous Non-small Cell Lung Cancer
AstraZeneca878 enrolled282 locationsNCT06627647
Recruiting
Phase 3
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Non-small Cell Lung Cancer (NSCLC)
AstraZeneca400 enrolled197 locationsNCT07291037
Recruiting
Phase 2
Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients
MetastasesHER2 + Gastric CancerFirst Line Therapy+2 more
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest80 enrolled20 locationsNCT07176312